KR910015568A - 신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체 - Google Patents

신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체 Download PDF

Info

Publication number
KR910015568A
KR910015568A KR1019910002022A KR910002022A KR910015568A KR 910015568 A KR910015568 A KR 910015568A KR 1019910002022 A KR1019910002022 A KR 1019910002022A KR 910002022 A KR910002022 A KR 910002022A KR 910015568 A KR910015568 A KR 910015568A
Authority
KR
South Korea
Prior art keywords
compound
separated
piperidino
formula
general formula
Prior art date
Application number
KR1019910002022A
Other languages
English (en)
Other versions
KR930011041B1 (ko
Inventor
윌리엄 버틀러 토드
Original Assignee
제이. 트레보 럼
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이. 트레보 럼, 화이자 인코포레이티드 filed Critical 제이. 트레보 럼
Publication of KR910015568A publication Critical patent/KR910015568A/ko
Application granted granted Critical
Publication of KR930011041B1 publication Critical patent/KR930011041B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용가능한 그의 염.
    상기식에서, A 및 B는 함께 -CH2CH2-이거나, 서로 분리되어 각각 H이고; X는 CH2또는 O이며; X1은 H 또는 OH이고; Z는 H, F, Cl, Br 또는 OH이며; Z1은 H, F, Cl, Br 또는 (C1-C3)알킬이고; n은 0 또는 1이며; m은 0 또는 1 내지 6의 정수이다.
  2. 제1항에 있어서, 하기 일반식(Ia)의 시스 입체 화학식을 갖는 화합물.
    상기식에서, A 및 B는 서로 분리되어 있고; Z는 H, F, Cl 또는 OH이며; Z1은 H이고; m은 0.1 또는 2이며; x는 0이고; n은 1이다.
  3. 제2항에 있어서, Z가 크로만 환 시스템의 7-위치에 치환되며 OH인 화합물.
  4. 제1항에 있어서, 하기 일반식(Ib)의 트란스 입체 화학식을 갖는 화합물.
    상기식에서, A 및 B는 서로 분리되어 있고; Z는 OH이며; Z1은 H이고; m은 0.1 또는 2이며; x는 CH2이고; n은 1이다.
  5. 제4항에 있어서, Z가 테트라하이드로나프탈렌 환 시스템의 6-위치에 치환되며 OH인 화합물.
  6. 제1항에 있어서, A 및 B가 서로 분리되어 있으며, Z가 OH이고, Z1이 H이며, m이 0.1 또는 2이고, x가 CH2이며, n이 0인 화합물.
  7. 제6항에 있어서, X1이 OH이고, m이 0인 화합물.
  8. 하기 일반식(Ⅱ)의 화합물
    상기식에서, A 및 B는 함께 -CH2CH2- 이거나, A 및 B가 서로 분리되어 각각 H이고; G 및 J는 함께 O이거나, G 와 J가 서로 분리되어 G는 수소이고, J는 하이드록시이며; X는 CH2또는 O이며; X1은 H 또는 OH이며; Z1은 H, F, Cl, Br 또는 (C1-C3)알킬이고; Z3는 H, F, Cl, Br 또는 OR이며; R은 H 또는 통상의 하이드록시 보호 그룹이고; n은 0 또는 1이며; m은 0 또는 1 내지 6의 정수이고; 단, G 및 J가 분리되어 있을때 Z3는 OR1이고, R1은 통상의 하이드록시 보호그룹이다.
    하기 일반식(Ⅲ)의 화합물.
    상기식에서, A 및 B는 함께 -CH2CH2- 이거나, A 및 B가 서로 분리되어 각각 H이고; X1은 H 또는 OH이며; Z1은 H, F, Cl,Br 또는 (C1-C3)알킬이고; Z3은 H, F, Cl, Br 또는 OR이며; R은 H 또는 통상의 하이드록시 보호 그룹이고; m은 0 또는1 내지 6의 정수이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910002022A 1990-02-06 1991-02-06 신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체 KR930011041B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US90/00674 1990-02-06
PCT/US1990/000674 WO1991012005A1 (en) 1990-02-06 1990-02-06 Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
US90/00674 1990-02-06

Publications (2)

Publication Number Publication Date
KR910015568A true KR910015568A (ko) 1991-09-30
KR930011041B1 KR930011041B1 (ko) 1993-11-20

Family

ID=22220666

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910002022A KR930011041B1 (ko) 1990-02-06 1991-02-06 신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체

Country Status (29)

Country Link
US (1) US5356905A (ko)
EP (1) EP0441506B1 (ko)
JP (1) JPH0768214B2 (ko)
KR (1) KR930011041B1 (ko)
CN (1) CN1029960C (ko)
AT (1) ATE108787T1 (ko)
AU (1) AU626490B2 (ko)
BR (1) BR9100490A (ko)
CA (1) CA2035653C (ko)
CZ (1) CZ286218B6 (ko)
DE (2) DE69102893T4 (ko)
DK (1) DK0441506T3 (ko)
EG (1) EG19643A (ko)
ES (1) ES2056571T3 (ko)
FI (1) FI94957C (ko)
HU (1) HU222726B1 (ko)
IE (1) IE63836B1 (ko)
IL (1) IL97100A (ko)
MX (1) MX24433A (ko)
MY (1) MY105293A (ko)
NO (1) NO178399C (ko)
NZ (1) NZ237025A (ko)
PH (1) PH31061A (ko)
PL (1) PL164866B1 (ko)
PT (1) PT96664B (ko)
RU (1) RU2099339C1 (ko)
SK (1) SK281729B6 (ko)
WO (1) WO1991012005A1 (ko)
ZA (1) ZA91830B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654554B2 (en) * 1991-04-18 1994-11-10 Pfizer Inc. Prodrug esters of phenolic 2-piperidino-1-alkanols
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
NZ275151A (en) * 1994-01-31 1998-02-26 Pfizer 3r*4s*3-[4-(4-fluorophenyl)-4-hydroxy-piperidin-1-yl]-chroman-4 ,7-diol; isomers and salts
CZ290988B6 (cs) * 1994-08-18 2002-11-13 Pfizer Inc. Deriváty fenolu a farmaceutický prostředek na jejich bázi
US6258827B1 (en) 1995-05-26 2001-07-10 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective NMDA antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
EP1235572A2 (en) 1999-10-29 2002-09-04 MERCK SHARP &amp; DOHME LTD. Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
UA75392C2 (en) 2001-02-23 2006-04-17 Merck & Co Inc N-substituted non-aryl heterocyclic antagonists nmda/nr2b
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
WO2005034878A2 (en) * 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (ko) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
DE2507782A1 (de) * 1975-02-22 1976-09-02 Merck Patent Gmbh Tetralon- und indanon-derivate sowie verfahren zu ihrer herstellung
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
ATE23718T1 (de) * 1981-09-25 1986-12-15 Beecham Group Plc Benzopyran-verbindungen mit pharmazeutischer wirkung.
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds

Also Published As

Publication number Publication date
CN1029960C (zh) 1995-10-11
PL164866B1 (pl) 1994-10-31
MY105293A (en) 1994-09-30
IE63836B1 (en) 1995-06-14
IL97100A (en) 1996-06-18
EG19643A (en) 1995-09-30
PL288949A1 (en) 1991-07-29
FI94957C (fi) 1995-11-27
ES2056571T3 (es) 1994-10-01
US5356905A (en) 1994-10-18
IL97100A0 (en) 1992-03-29
PT96664B (pt) 1998-07-31
DE69102893T4 (de) 1995-08-10
NO178399B (no) 1995-12-11
CZ286218B6 (cs) 2000-02-16
JPH0768214B2 (ja) 1995-07-26
NZ237025A (en) 1992-11-25
WO1991012005A1 (en) 1991-08-22
DE69102893D1 (de) 1994-08-25
FI923527A (fi) 1992-08-05
AU7029391A (en) 1991-09-05
DE69102893T2 (de) 1994-11-03
PT96664A (pt) 1991-10-31
DK0441506T3 (da) 1994-09-05
ATE108787T1 (de) 1994-08-15
EP0441506A2 (en) 1991-08-14
NO178399C (no) 1996-03-20
BR9100490A (pt) 1991-10-29
CS25091A3 (en) 1991-09-15
CN1053923A (zh) 1991-08-21
EP0441506A3 (en) 1991-11-21
EP0441506B1 (en) 1994-07-20
FI94957B (fi) 1995-08-15
NO923081D0 (no) 1992-08-05
PH31061A (en) 1998-02-05
ZA91830B (en) 1992-09-30
CA2035653A1 (en) 1991-08-07
CA2035653C (en) 1999-12-21
NO923081L (no) 1992-08-05
AU626490B2 (en) 1992-07-30
KR930011041B1 (ko) 1993-11-20
JPH04211058A (ja) 1992-08-03
RU2099339C1 (ru) 1997-12-20
FI923527A0 (fi) 1992-08-05
DE9101346U1 (de) 1991-06-06
HU222726B1 (hu) 2003-09-29
MX24433A (es) 1993-05-01
SK281729B6 (sk) 2001-07-10
IE910372A1 (en) 1991-08-14

Similar Documents

Publication Publication Date Title
KR910015568A (ko) 신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체
FI910857A0 (fi) Foerfarande foer framstaellning av oxetanoner.
FI864527A (fi) Tricyklofoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandning.
AR001036A1 (es) Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento
KR860001779A (ko) 퀴논 유도체의 제조방법
KR840001156A (ko) 벤지미다졸 유도체의 제조방법
ES8104321A1 (es) Procedimiento para separar un derivado de alquil-cetohexopi-ranosida
KR850004492A (ko) 옥시캄의 엔올 에테르 유도체의 제조방법
KR850006187A (ko) 신규 히달토인(Hydantoin) 유도체의 제조방법
KR850007252A (ko) 하이드록시-4-2h-1-벤조티오피란-2-온 유도체의 제조방법
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
FI892991A0 (fi) Nya 4,5,7,8-tetrahydro-6h-tiazolo/5,4-d /azepiner, deras framstaellning och deras anvaendning som laekemedel.
KR840006254A (ko) 7-치환된-3-비닐-3-세펨화합물의 제조방법
ES8404347A1 (es) Un procedimiento para la preparacion de derivados de fenilpiperazina.
EP0347123A3 (en) Dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties
KR830004220A (ko) 약리적 활성 펩티드
KR840001152A (ko) 신규 복소환(複素環) 화합물의 제법
KR870003107A (ko) 키산틴 유도체의 제조방법
KR920702685A (ko) 4,6-o- 히드록시포스포릴글루코사민 유도체
ATE9329T1 (de) Indol- und indolin-derivate.
KR910018371A (ko) 이소크로메인 유도체
KR960017659A (ko) 새로운 피롤리딘 유도체와 그 제조방법
KR900016184A (ko) 1, 3-디옥산 유도체
KR860004008A (ko) 부타놀유도체의 제법
KR930012679A (ko) 옥시벤젠 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031015

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee